Posts

Gilead's HIV PrEP Franchise Hits $1B+ Quarterly Sales, With Yeztugo Growth Tempered by Durability Concerns

on

Atea's hep C pill equal to Gilead's

on

Gilead and Merck Release Key HIV Data

on

Who pays the best (and worst) in biopharma? A look at typical employee salaries

on

Gilead highlights Tubulis ADC ovarian cancer data as validation of buyout decision

on

Gilead's Hepcludex Wins FDA Approval for Hepatitis D After Prior Manufacturing Snag

on

Gilead Cuts Over 300 Jobs at Arcellx Post-$7.8B Acquisition as BioNTech Plans 1,860 Layoffs

on

Gilead Loosens Ties with Arcus After TIGIT Drug Domvanalimab Fails Phase 3 Trial

on

Gilead Scales Back M&A After $14.77B Spree but Open to Compelling Deals

on

Gilead Continues Dealmaking Streak with $3.15B Tubulis Buy for ADCs

on

Gilead Acquires Tubulis for $3.15B Upfront to Strengthen Oncology ADC Pipeline

on

Gilead Declines Option on Assembly Biosciences' Phase 1 HBV Antiviral ABI-4334

on

Gilead and Merck Advance Daily HIV Treatment Pills with Positive Late-Stage Data at CROI 2026

on

Biopharma Bites: uniQure Pauses AMT-191 Dosing, GSK's Nucala Gets EU Nod, Gilead CAR-T Label Update

on

Gilead's $35M Herpes Deal with Assembly Biosciences and Recent FDA Approvals

on

FDA OKs Sarepta Study of New Immune Suppression Approach with Elevidys; Gilead Acquires Preclinical TREX1 Program

on

Spotlight On: Big Pharma's Big Bets on In Vivo Cell Therapy

on

Compugen Reports Third Quarter 2025 Results: Earnings Beat, Clinical Progress, and Cash Runway Extended

on

Gilead and Arcus Report Positive Results for TIGIT Approach in Gastric Cancer Trial

on

Gilead's Kite to Acquire Interius for $350M, Advancing In Vivo CAR-T Therapy

on